Diagnostic Product Sample Clauses

The 'Diagnostic Product' clause defines what constitutes a diagnostic product within the context of the agreement. It typically specifies the types of products, such as medical devices, assays, or test kits, that are designed to detect, diagnose, or monitor diseases or conditions. This clause clarifies the scope of products covered by the contract, ensuring that both parties understand which items are subject to the agreement’s terms and obligations, thereby preventing disputes over applicability.
Diagnostic Product. The provisions of Sections 11.3, 11.4 and 11.5 shall not apply to a diagnostic Product. If Roche desires to research, develop or commercialize a diagnostic Product in the Territory in the Field, then Roche shall have the right to acquire all necessary rights from PTC and the Parties shall negotiate in good faith appropriate economic terms for Roche’s development or commercialization of such diagnostic Product.
View SourceView Similar (3)
Diagnostic Product. In the event OncoMed seeks to Research, Develop and Commercialize a diagnostic that pertains to how a Collaboration Compound may be used in clinical practice, OncoMed will consult first with GSK on a Development and Commercialization plan for any such diagnostic product prior to approaching any Third Party with whom OncoMed could work to Develop such diagnostic, either by means of a collaboration or a license. If OncoMed and GSK do not enter into an agreement for the Development and Commercialization of any such diagnostic within [***] after the date of OncoMed’s initial request for such consultation with GSK, OncoMed will be free to initiate discussions with Third Parties and may enter into such an agreement, either with GSK or with a Third Party, on terms that, in OncoMed’s sole discretion, are acceptable to OncoMed. In the event OncoMed enters into an agreement for the Development and Commercialization of any such diagnostic with a Third Party, subject to any obligations of confidentiality with such Third Party, OncoMed will consult with GSK regarding whether the Development and Commercialization plan for such diagnostic is [***]. OncoMed will use good faith efforts to [***].
View SourceView Similar (3)
Diagnostic Product. The term “
View SourceView Similar (2)
Diagnostic Product. Confidential Treatment Requested * For the purpose of 4.4 b) * .
View SourceView Similar (2)
Diagnostic Product. Milestone Fee --------- --- Initiation of Clinical Trials [***] Initial of Pivotal Trials [***] First Regulatory Approval in the U.S. [***]
View SourceView Similar (2)
Diagnostic Product. In the event that ▇▇▇▇▇ intends to [***], then its shall [***]. ▇▇▇▇▇ [***]diagnostic product [***] until [***] in accordance with this Section 6.1. In the event that [***], the Parties will [***] the [***] such diagnostic product, [***]). If [***], or if [***], then ▇▇▇▇▇ [***] develop and commercialize such diagnostic product, [***] such diagnostic product, [***], ▇▇▇▇▇ [***]. For the avoidance of doubt, Mirna’s [***] applies and accrues with respect to [***] during the Term.
View Source
Diagnostic Product. Diagnostic Product means an HSP90 targeting moiety (including inhibitors) joined to a diagnostic agent via a linker.
View Source
Diagnostic Product. For Diagnostic Products, the royalty rate will be (a) [***] for a companion Diagnostic Product to an Agreement Product and (b) [***] for any other Diagnostic Product.
View Source

Related to Diagnostic Product

  • Licensed Product The term “Licensed Product” shall mean any product (a) the manufacture, use, importation, sale or offer for sale of which would, in the absence of the license granted by this Agreement, infringe a Valid Claim of any of the Licensed Patent Rights, or (b) that is comprised of, utilizes or incorporates Licensed Biological Materials, or (c) that is discovered, developed or made using a Licensed Process.

  • Licensed Products Lessee will obtain no title to Licensed Products which will at all times remain the property of the owner of the Licensed Products. A license from the owner may be required and it is Lessee's responsibility to obtain any required license before the use of the Licensed Products. Lessee agrees to treat the Licensed Products as confidential information of the owner, to observe all copyright restrictions, and not to reproduce or sell the Licensed Products.

  • Combination Product The term “

  • Combination Products If a LICENSED PRODUCT is sold to any third party in combination with other products, devices, components or materials that are capable of being sold separately and are not subject to royalties hereunder (“OTHER PRODUCTS,” with the combination of products being referred to as “COMBINATION PRODUCTS” and the Other Product and Licensed Product in such Combination Product being referred to as the “COMPONENTS”), the NET SALES of such LICENSED PRODUCT included in such COMBINATION PRODUCT shall be calculated by multiplying the NET SALES of the COMBINATION PRODUCT by the fraction A/(A+B), where A is the average NET SALES price of such LICENSED PRODUCT in the relevant country, as sold separately, and B is the total average NET SALES price of all OTHER PRODUCTS in the COMBINATION PRODUCT in the relevant country, as sold separately. If, in any country, any COMPONENT is not sold separately, NET SALES for royalty determination shall be determined by the formula [C / (C+D)], where C is the aggregate average fully absorbed cost of the Licensed Product components during the prior Royalty Period and D is the aggregate average fully absorbed cost of the other essential functional components during the prior Royalty Period, with such costs being determined in accordance with generally accepted accounting principles. To the extent that any SUBLICENSE INCOME relates to a COMBINATION PRODUCT or is otherwise calculated based on the value of one or more licenses or intellectual property rights held by the COMPANY, an AFFILIATE or SUBLICENSEE, COMPANY shall determine in good faith and report to THE PARTIES the share of such payments reasonably attributable to COMPANY’s or such AFFILIATE’s sublicense of the rights granted hereunder, based upon their relative importance and proprietary protection, which portion shall be the SUBLICENSE INCOME. THE PARTIES shall have the right to dispute such sharing determination in accordance with the dispute provisions of the AGREEMENT.

  • Product NYISO will provide Energy Resource Interconnection Service and Capacity Resource Interconnection Service to Developer at the Point of Interconnection.